Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion

Hongkwan Cho, Matthew J. Hartsock, Zhenhua Xu, Meihua He, Elia J Duh

Research output: Contribution to journalArticle

Abstract

Background: Retinal ischemia results in neuronal degeneration and contributes to the pathogenesis of multiple blinding diseases. Recently, the fumaric acid ester dimethyl fumarate (DMF) has been FDA-approved for the treatment of multiple sclerosis, based on its neuroprotective and anti-inflammatory effects. Its potential role as a neuroprotective agent for retinal diseases has received little attention. In addition, DMF's mode of action remains elusive, although studies have suggested nuclear factor erythroid 2-related factor 2 (Nrf2) activation as an important mechanism. Here we investigated the neuroprotective role of monomethyl fumarate (MMF), the biologically active metabolite of DMF, in retinal ischemia-reperfusion (I/R) injury, and examined the role of Nrf2 in mediating MMF action. Methods: Wild-type C57BL/6J and Nrf2 knockout (KO) mice were subjected to 90min of retinal ischemia followed by reperfusion. Mice received daily intraperitoneal injection of MMF. Inflammatory gene expression was measured using quantitative reverse transcription PCR (qRT-PCR) at 48h after I/R injury. Seven days after I/R, qRT-PCR for Nrf2 target gene expression, immunostaining for Müller cell gliosis and cell loss in the ganglion cell layer (GCL), and electroretinography for retinal function were performed. Results: The results of this study confirmed that MMF reduces retinal neurodegeneration in an Nrf2-dependent manner. MMF treatment significantly increased the expression of Nrf2-regulated antioxidative genes, suppressed inflammatory gene expression, reduced Müller cell gliosis, decreased neuronal cell loss in the GCL, and improved retinal function measured by electroretinogram (ERG) after retinal I/R injury in wild-type mice. Importantly, these MMF-mediated beneficial effects were not observed in Nrf2 KO mice. Conclusions: These results indicate that fumaric acid esters (FAEs) exert a neuronal protective function in the retinal I/R model and further validate Nrf2 modulation as a major mode of action of FAEs. This suggests that DMF and FAEs could be a potential therapeutic agent for activation of the Nrf2 pathway in retinal and possibly systemic diseases.

Original languageEnglish (US)
Article number239
JournalJournal of Neuroinflammation
Volume12
Issue number1
DOIs
StatePublished - Dec 21 2015

Fingerprint

Fumarates
Reperfusion
Ischemia
Reperfusion Injury
Gliosis
Gene Expression
Knockout Mice
Ganglia
Reverse Transcription
Neuroprotection
Electroretinography
Retinal Diseases
Polymerase Chain Reaction
Neuroprotective Agents
Intraperitoneal Injections
Multiple Sclerosis
Anti-Inflammatory Agents
Therapeutics

Keywords

  • Fumaric acid esters/monomethyl fumarate
  • Ischemia-reperfusion
  • Neurodegeneration
  • Retina

ASJC Scopus subject areas

  • Neuroscience(all)
  • Cellular and Molecular Neuroscience
  • Neurology
  • Immunology

Cite this

Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. / Cho, Hongkwan; Hartsock, Matthew J.; Xu, Zhenhua; He, Meihua; Duh, Elia J.

In: Journal of Neuroinflammation, Vol. 12, No. 1, 239, 21.12.2015.

Research output: Contribution to journalArticle

@article{cf6efc38ba0a4313ad07c1d03539fa56,
title = "Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion",
abstract = "Background: Retinal ischemia results in neuronal degeneration and contributes to the pathogenesis of multiple blinding diseases. Recently, the fumaric acid ester dimethyl fumarate (DMF) has been FDA-approved for the treatment of multiple sclerosis, based on its neuroprotective and anti-inflammatory effects. Its potential role as a neuroprotective agent for retinal diseases has received little attention. In addition, DMF's mode of action remains elusive, although studies have suggested nuclear factor erythroid 2-related factor 2 (Nrf2) activation as an important mechanism. Here we investigated the neuroprotective role of monomethyl fumarate (MMF), the biologically active metabolite of DMF, in retinal ischemia-reperfusion (I/R) injury, and examined the role of Nrf2 in mediating MMF action. Methods: Wild-type C57BL/6J and Nrf2 knockout (KO) mice were subjected to 90min of retinal ischemia followed by reperfusion. Mice received daily intraperitoneal injection of MMF. Inflammatory gene expression was measured using quantitative reverse transcription PCR (qRT-PCR) at 48h after I/R injury. Seven days after I/R, qRT-PCR for Nrf2 target gene expression, immunostaining for M{\"u}ller cell gliosis and cell loss in the ganglion cell layer (GCL), and electroretinography for retinal function were performed. Results: The results of this study confirmed that MMF reduces retinal neurodegeneration in an Nrf2-dependent manner. MMF treatment significantly increased the expression of Nrf2-regulated antioxidative genes, suppressed inflammatory gene expression, reduced M{\"u}ller cell gliosis, decreased neuronal cell loss in the GCL, and improved retinal function measured by electroretinogram (ERG) after retinal I/R injury in wild-type mice. Importantly, these MMF-mediated beneficial effects were not observed in Nrf2 KO mice. Conclusions: These results indicate that fumaric acid esters (FAEs) exert a neuronal protective function in the retinal I/R model and further validate Nrf2 modulation as a major mode of action of FAEs. This suggests that DMF and FAEs could be a potential therapeutic agent for activation of the Nrf2 pathway in retinal and possibly systemic diseases.",
keywords = "Fumaric acid esters/monomethyl fumarate, Ischemia-reperfusion, Neurodegeneration, Retina",
author = "Hongkwan Cho and Hartsock, {Matthew J.} and Zhenhua Xu and Meihua He and Duh, {Elia J}",
year = "2015",
month = "12",
day = "21",
doi = "10.1186/s12974-015-0452-z",
language = "English (US)",
volume = "12",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion

AU - Cho, Hongkwan

AU - Hartsock, Matthew J.

AU - Xu, Zhenhua

AU - He, Meihua

AU - Duh, Elia J

PY - 2015/12/21

Y1 - 2015/12/21

N2 - Background: Retinal ischemia results in neuronal degeneration and contributes to the pathogenesis of multiple blinding diseases. Recently, the fumaric acid ester dimethyl fumarate (DMF) has been FDA-approved for the treatment of multiple sclerosis, based on its neuroprotective and anti-inflammatory effects. Its potential role as a neuroprotective agent for retinal diseases has received little attention. In addition, DMF's mode of action remains elusive, although studies have suggested nuclear factor erythroid 2-related factor 2 (Nrf2) activation as an important mechanism. Here we investigated the neuroprotective role of monomethyl fumarate (MMF), the biologically active metabolite of DMF, in retinal ischemia-reperfusion (I/R) injury, and examined the role of Nrf2 in mediating MMF action. Methods: Wild-type C57BL/6J and Nrf2 knockout (KO) mice were subjected to 90min of retinal ischemia followed by reperfusion. Mice received daily intraperitoneal injection of MMF. Inflammatory gene expression was measured using quantitative reverse transcription PCR (qRT-PCR) at 48h after I/R injury. Seven days after I/R, qRT-PCR for Nrf2 target gene expression, immunostaining for Müller cell gliosis and cell loss in the ganglion cell layer (GCL), and electroretinography for retinal function were performed. Results: The results of this study confirmed that MMF reduces retinal neurodegeneration in an Nrf2-dependent manner. MMF treatment significantly increased the expression of Nrf2-regulated antioxidative genes, suppressed inflammatory gene expression, reduced Müller cell gliosis, decreased neuronal cell loss in the GCL, and improved retinal function measured by electroretinogram (ERG) after retinal I/R injury in wild-type mice. Importantly, these MMF-mediated beneficial effects were not observed in Nrf2 KO mice. Conclusions: These results indicate that fumaric acid esters (FAEs) exert a neuronal protective function in the retinal I/R model and further validate Nrf2 modulation as a major mode of action of FAEs. This suggests that DMF and FAEs could be a potential therapeutic agent for activation of the Nrf2 pathway in retinal and possibly systemic diseases.

AB - Background: Retinal ischemia results in neuronal degeneration and contributes to the pathogenesis of multiple blinding diseases. Recently, the fumaric acid ester dimethyl fumarate (DMF) has been FDA-approved for the treatment of multiple sclerosis, based on its neuroprotective and anti-inflammatory effects. Its potential role as a neuroprotective agent for retinal diseases has received little attention. In addition, DMF's mode of action remains elusive, although studies have suggested nuclear factor erythroid 2-related factor 2 (Nrf2) activation as an important mechanism. Here we investigated the neuroprotective role of monomethyl fumarate (MMF), the biologically active metabolite of DMF, in retinal ischemia-reperfusion (I/R) injury, and examined the role of Nrf2 in mediating MMF action. Methods: Wild-type C57BL/6J and Nrf2 knockout (KO) mice were subjected to 90min of retinal ischemia followed by reperfusion. Mice received daily intraperitoneal injection of MMF. Inflammatory gene expression was measured using quantitative reverse transcription PCR (qRT-PCR) at 48h after I/R injury. Seven days after I/R, qRT-PCR for Nrf2 target gene expression, immunostaining for Müller cell gliosis and cell loss in the ganglion cell layer (GCL), and electroretinography for retinal function were performed. Results: The results of this study confirmed that MMF reduces retinal neurodegeneration in an Nrf2-dependent manner. MMF treatment significantly increased the expression of Nrf2-regulated antioxidative genes, suppressed inflammatory gene expression, reduced Müller cell gliosis, decreased neuronal cell loss in the GCL, and improved retinal function measured by electroretinogram (ERG) after retinal I/R injury in wild-type mice. Importantly, these MMF-mediated beneficial effects were not observed in Nrf2 KO mice. Conclusions: These results indicate that fumaric acid esters (FAEs) exert a neuronal protective function in the retinal I/R model and further validate Nrf2 modulation as a major mode of action of FAEs. This suggests that DMF and FAEs could be a potential therapeutic agent for activation of the Nrf2 pathway in retinal and possibly systemic diseases.

KW - Fumaric acid esters/monomethyl fumarate

KW - Ischemia-reperfusion

KW - Neurodegeneration

KW - Retina

UR - http://www.scopus.com/inward/record.url?scp=84953838145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953838145&partnerID=8YFLogxK

U2 - 10.1186/s12974-015-0452-z

DO - 10.1186/s12974-015-0452-z

M3 - Article

C2 - 26689280

AN - SCOPUS:84953838145

VL - 12

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 239

ER -